Abstract 107P
Background
Metastatic non-clear cell renal cell carcinoma (mnccRCC) currently lacks standard first-line treatment options. This study evaluated the effectiveness and safety of ICI plus tyrosine kinase inhibitor (TKI) in mnccRCC patients through multi-center real-world evidence, encompassing the largest sample size to date.
Methods
We conducted a retrospective analysis of treatment-naive metastatic non-clear cell renal cell carcinoma (mnccRCC) patients who received either TKI monotherapy or TKI + ICI combination therapy at four hospitals in China. Baseline characteristics were recorded, and comparisons were made between the two groups in terms of objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and the incidence of adverse events (AEs).
Results
A total of 214 mnccRCC patients were enrolled from the four hospitals: 122 in the TKI monotherapy group and 92 in the TKI + ICI combination group. The median follow-up time was 36.5 months (interquartile range [IQR], 24.2–57.0), with a median age of 49 years and a majority of male patients (70.6%). Compared to the TKI group, the TKI + ICI group showed a significantly higher objective response rate (29.4% vs. 16.4%, P < 0.01) and disease control rate (78.3% vs. 48.4%, P < 0.01). Additionally, the combination therapy group had a longer progression-free survival [median PFS (95% CI): 15.2 (6.6–23.7) months vs. 5.9 (4.3–7.5) months, P < 0.001] and a longer overall survival [median OS (95% CI): not reached vs. 38.5 (26.6–50.4) months, P = 0.019]. The incidence of grade 3 or higher treatment-related adverse events was slightly higher in the combination therapy group, but the difference was not statistically significant (35.8% vs. 23.7%, P = 0.079).
Conclusions
Our retrospective real-world study demonstrates that, compared to TKI monotherapy, the combination of ICI and TKI significantly improves progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC), with manageable safety. This study provides stronger evidence for the pharmacological treatment of metastatic non-clear cell renal cell carcinoma.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract